The adenosine A 2A receptor (A 2A R) is highly concentrated in the striatum, and a therapeutic target for Parkinson's disorder (PD) and Huntington's disease. High affinity and selective radiolabeled A 2A R antagonists can be important research and diagnostic tools for PD. Positron Emission Tomography (PET) can play an important role by measuring radiolabeled A 2A antagonists non-invasively in the brain. However, till date no complete review on A 2A R PET ligands is available. The present article has been therefore focused on available PET tracers for A 2A R and their detailed biological evaluation in rodents, nonhuman primates and humans. Drug design and development by molecular modeling including new lead structures that are potential candidates for radiolabeling and mapping of cerebral A 2A Rs is discussed in the present article. A brief overview of functions of adenosine in health and disease, including the relevance of A 2A R for PD has also been presented.
INTRODUCTION
Adenosine, an endogenous ligand, functions as a cytoprotective and neuromodulator in response to stress to an organ or tissue under both physiological and pathophysiological conditions. It elicits intracellular signaling cascades through four subtypes of G-protein coupled adenosine receptors (ARs) namely A 1, A 2A, A 2B and A 3 (A 1 R , A 2A R, A 2B R and A 3 R, respectively) [1] [2] [3] [4] .
Cytoprotective mechanisms may be indicated by an increased blood supply (vasodilatation or angiogenesis), cerebral and cardiac preconditioning and / or suppression of inflammation [5] . Adenosine is believed to play an important role in promoting sleep and suppressing arousal, cognition and memory, neuronal damage and degeneration as well as neuronal maturation [5, 6] . Furthermore, adenosine is a local modulator for other neurotransmitters and counteracts glutamate excitatory effects. As a result, ARs are promising targets for investigation and treatment of cerebral and cardiac diseases, ischemic renal injury, endocrine, pain, and sleep disorders, immune and inflammatory disorders and cancers [6] [7] [8] [9] [10] .
In the last two decades, the most extensively studied AR subtypes are high affinity adenosine A 1 receptors (A 1 Rs) and *Address correspondence to this author at the Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, The Netherlands; Tel: +31-50-3613375; Telefax: +31-50-3611687; E-mail: s.shivashankar@umcg.nl adenosine A 2A receptors (A 2A Rs), because adenosine activates these receptors in nanomolar concentrations. These subtypes are well-characterized biochemically and pharmacologically [11, 12] . The high affinity A 2A subtype, when coupled with G-proteins, exhibits a lower affinity to adenosine, activation of A 2A R assists neuronal function of neurotropic receptors like tropomyosin-related kinase B (TrkB) receptors and enhances neuronal communication [13] . A 2A Rs stimulate adenylyl cyclase activity via Gs proteins [14] . They can also activate potassium channels but inactivate Ca 2+ channels, modulate the activities of phospholipases C, D, and A 2, and upregulate mitogen-activated protein kinases and inflammatory cytokines like IL-1 [14] .
The regional distribution of A 2A R within the human brain is more restricted than that of A 1 Rs. A 2A Rs are abundantly expressed in the basal ganglia and highest levels of expression occur in the substantia nigra (striatum Bmax 313 ± 10 fmol / mg protein) [15] , nucleus accumbens and olfactory tubercle whereas A 1 Rs are highly expressed in the cerebral cortex, hippocampus, and dorsal horn of spinal cord [16] . Lower densities of A 2A Rs occur in the amygdala, cerebellum, brainstem and hypothalamus [17] [18] [19] . A 2A Rs are implied in several cerebral diseases such as Parkinson's disease (PD), Huntington's disease, Alzheimer's disease, attention deficit hyperactivity and panic disorders, schizophrenia, pain, and sleep disorders. Also, A 2A Rs play an important role in cardiac diseases, immune and inflammatory disorders, and ischemic kidney injury [7] [8] [9] [10] 20] .
Symptomatic dopaminergic replacement strategy using L-DOPA and dopamine agonists is the current therapy for PD [21, 22] . However, with disease progression the therapy suffers from several limitations like negligible effects on non-motor symptoms, reduced effectivity in reverting motor impairment, unwanted side effects like dyskinesia, motor fluctuations and neuropsychiatric complications and importantly, fails to delay disease progression [23] [24] [25] [26] . A 2A Rs are mainly restricted to the indirect striatal output function [i.e.,GABAergic neurons projecting to the globus pallidus (GP), pars externa] and are co-localized with dopamine D 2 receptors (D 2 Rs) in the striatum. Along with D 2 Rs, blockade of A 2A Rs dampens the hyperactivity of the indirect dopamine pathway observed during PD, restores correct movement execution and suppresses the neurodegenerative process and hence has raised a lot of interest due to unmet medical needs of PD [26] . Co-localization and synergistic interaction between A 2A R and metabotropic glutamate subtype 5 (mGlu5) receptor make A 2A Rs an important target for the therapy of PD [27, 28] . Heteromeric forms like A 1 /A 2A , D 3 /A 2A and cannabinoid CB 1 /A 2A have all been observed [29, 30] . In addition, evidence for heterotrimers like CB 1 /A 2A /D 2 , A 2A /D 2 / mGlu5 was also reported [29, 31] .
Apart from its central location, A 2A Rs present in peripheral organs like heart, kidney, liver, muscle and lung [32] . In heart, adenosine is an important mediator in cardioprotective action [5, 32] . Myocardial protection action of adenosine is mediated mainly through A 1 R and A 2A R. Activation of A 2A Rs causes coronary vasodilatation [33] , increases myocardial contractibility [34] , relaxes smooth muscle and inhibits cytokine production, increases coronary blood flow and inhibits platelet aggregation [5] . A 2A R via the action of adenosine help in regulation of physiological functions of skeletal muscle like glucose uptake, blood flow and contractile force [35] .
Positron emission tomography (PET) can contribute important information in drug development resulting in a more rapid evaluation of novel compounds. High affinity and selective radiolabeled A 2A R antagonists can be used to assess changes of A 2A R density during the progression of disease and the affect of therapy on such changes. Moreover, A 2A R ligands can be employed to assess occupancy of the receptor population by therapeutic drugs in the human brain, which will allow correlation of receptor occupancy and therapeutic effects [36, 37] . PET is a non-invasive technique allowing studies of physiological processes in the brain of normal individuals and patients with neurologic illness [3] . Furthermore, PET can help to increase diagnostic specificity for dopamine-deficient parkinsonian syndromes and justify management decisions at initial stages of disease. Along with single photon emission computed tomography (SPECT) and proton magnetic resonance spectroscopy, 18 F-DOPA PET is useful in discriminating atypical parkinsonian disorders (multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration) from idiopathic PD with up to 80% specificity [38] .
On the basis of these considerations, several A 2A R antagonists (both xanthine and non-xanthine derivatives) have been produced and some of them are being tested as treatment for PD in several clinical trials as well as in preclinical studies [35, 39- [3] .
Adenosine antagonists and their PET tracers have been the topic of many reviews [2, 3, 21, [51] [52] [53] [54] [55] [56] [57] [58] [59] . These reviews have provided a discussion on adenosine functions in health and disease, PET tracers for mapping adenosine receptors (mainly A 1 R) and the development of potential novel radioligands. However, to date, no comprehensive review on PET ligands for A 2A R is available. The major goals of the current article is three-fold: 1) to present an overview of A 2A R antagonists used as PET tracers, 2) to summarize preclinical and clinical A 2A R imaging data, and 3) to highlight the design and development of new lead compounds as potential tracers for mapping of A 2A Rs.
A 2A R PET TRACERS
A 2A R antagonist PET tracers ( Fig. 1) can be mainly divided into two classes.
1. Xanthine PET tracers 2. Non-xanthine PET tracers
Xanthine Ligands
All xanthine type radioligands were synthesized either by N-or O-methylation of the corresponding desmethyl compounds using primarily [ 11 C]CH 3 I with sufficient radiochemical yields suitable for routine use [60] [61] [62] [63] [64] . (Table 1 ). In one of the radioligand syntheses, the more reactive methylating agent [ 11 C]CH 3 OTf has been used to achieve high radiochemical yield. However, reaction temperature, time and specific activity were not mentioned in the literature [65] . All xanthine analogues suffer from a serious photoisomerization (Fig. 1) . The styryl group in the xanthine scaffold is isomerized to form a stable equilibrium mixture of E-isomer and Z-isomer in the presence of light. Therefore in experimental and clinical studies, all procedures should be carefully carried out under dim light [3] .
In Vitro and Preclinical Studies
Researchers earlier emphasized the selectivity of KF17837 towards A 2A R [67] . However, in a later study its specificity for A 2A R was questioned because in dilute solution this styrylxanthine undergoes photoisomerisation to the less active Z-isomer (82 %) [68] . The Z-isomer has about 860 fold lower affinity (K i value, 860 ± 120 nM) for the A 2A R than the E-isomer (1.0 ± 0.1 nM) [60, 68] .
Suzuki and co-workers developed the xanthine compound KF17837 [69, 70] and two other groups successfully labeled its desmethyl compound with carbon-11 by Nmethylation reaction using [ 11 C]methyl iodide ( Table 1) . Radiosynthesis was carried out under dim light in an amber glass vial, which preserved the E-isomer over the entire period of study [60, 62] . Biodistribution studies showed highest radioactivity uptake [13 % injected dose per gram (% ID / g)] in the heart at 5 min after injection of [ 11 C]KF17837 in normal healthy mice but falling gradually thereafter. A high and saturable uptake of tracer by the mouse heart confirmed its usefulness for mapping myocardial adenosine receptors [60] . Similar results were observed with a dynamic PET scanning of the heart in rabbits [71] . Regional brain distribution showed a higher uptake in striatum than in other regions (striatum / cerebellum ratio approximately 2.0 at 60 min).
The compound's affinity for A 2A R-rich striatum was confirmed by carrier KF17837 co-injection and by sequential PET studies in the same rats using D 2 R ligand [ 11 C]Nmethylspiperone. Reduction by 68 % radioactivity in striatum after carrier injection at 30 min and also [ 11 C]KF17837 accumulated in the same brain regions as observed using [ 11 C]N-methylspiperone clearly indicating its specific uptake in the striatum [60] ( Table 2) .
Later studies were aimed at evaluation of [ 11 C]KF17837 as a central nervous system (CNS) tracer in rodents and monkey [72] . In vitro autoradiography (ARG) experiments in rats showed 2.3 -3.0 times higher striatal uptake than in other brain regions. On the contrary, results from a regional brain distribution study in mice, an ex vivo ARG study in rats and a PET study in a monkey suggested only slightly higher uptake in the striatum than in other brain regions (1.1 -1.5 times) ( Table 2) . Authors hypothesized that the in vivo receptor binding sites of xanthine type antagonists may be different from those of non-xanthine type A 2A R ligands as in vivo uptake of [ 11 C]KF17837 was not significantly decreased in a blocking study using subtype selective non-xanthine analogues such as SCH58621 or ZM241385 [73] . Their data indicated nonspecific binding and the presence of unknown but specific binding sites for [
11 C]KF17837 in the cortex and cerebellum. In this study no clear conclusion was reached concerning its potential to bind adenosine A 2B receptor (A 2B R) because at the time of the study there was no subtype selective A 2B R ligand. However, a weak A 2B antagonist, alloxazine, did not reduce [
11 C]KF17837 uptake in the brain [72] .
In addition, another group evaluated [ 11 C]KF17837 in monkey by PET examination. PET biodistribution studies using 3-D mode of data acquisition was used to express radioactivity retention in the striatum, cerebellum, and cerebral cortex (1.1, 1.0 and 0.8, respectively). Radioactive accumulation was significantly different from the known relative A 2A R densities in these regions [74] [75] [76] ( Table 2 ). The ligand has limited usefulness for mapping the cerebral A 2A R because of its limited diffusion through the blood brain barrier (BBB) and high non-specific binding. However, radiotracer uptake in the heart was rapid (maximum reached at 2 -4 min post injection). In a saturation binding experiment, there was an indication of competition between the labeled and unlabeled drugs for the same receptor binding sites in heart. Hence, authors suggested further investigation to establish the specificity of the interaction of this tracer with myocardial A 2A Rs and other potent and selective A 2A R antagonists (ZM241385 and SCH58261) could be considered as ligands for in vivo PET studies [62] . In conclusion, both groups clearly demonstrated limited suitability of [ 11 C]KF17837 for A 2A R quantification because of its low brain penetration and high degree of non-specific binding ( Table 2) . Investigated time is not an ideal point for comparing in vitro and in vivo studies as shown in (Table 2) .
A comprehensive comparison of four xanthine PET tracers (carbon-11 labeled KF17837, KF19631, TMSX and CSC) was made in order to search for a selective A 2A R ligand [61] . [ 11 C]CSC had similar characteristics as [
11 C]KF17837, but [ 11 C]CSC showed higher uptake in the lung and small intestine and it was cleared more rapidly. Another study described in detail optimization of the radiochemical synthesis of [ 11 C]CSC [63] . Also, significant [ 11 C]CSC accumulation in the lung was detected whereas autoradiographic investigations indicated uptake in the striatum, consistent with observations by Ishiwata et al. [61] . Dynamic PET scans in rabbits showed rapid uptake of the radiotracer in the brain in less than 2 min after injection. An in vivo competition study with cold CSC suggested that [ 11 C]CSC binds specifically to A 2A R in the rabbit brain [63] . However, the tracer's rapid clearance, different distribution pattern from other xanthine PET tracers (i.e., high uptake in small intestine and lungs) and low affinity made it unsuitable as a PET tracer for A 2A R.
Wang and co-workers continued their work in search for A 2A R tracers with high affinity and selectivity and found KF21213 with higher selectivity for A 2A R than KF17837 or KF18446 [66] . An in vitro study showed that K i values of KF21213 were 3.0 nM for A 2A R and >10,000 nM for A 1 R whereas for KF18446 they were 5.9 nM for A 2A R and 1600 nM for A 1 R ( Table 3 ). In mice, regional brain distribution data of [ 11 C]KF21213 suggested a high striatal uptake for the first 15 min followed by a gradual decrease. A very low uptake was seen in the cortex and cerebellum. As a result of this, high uptake ratios of striatum-to-cortex (8.6 ± 1.6) and striatum-to-cerebellum (10.5 ± 2.1) were found at 60 min Male Cynomolgus monkey (n = 2)** 1.05 -1.1 (20 min)
post injection. On the other hand, the uptake of [ 11 C]TMSX was higher in all three regions of brain but decreased more rapidly with time so that the striatum-to-cortex ratio was 2.8 ± 0.5 and striatum-to-cerebellum ratio was 2.7 ± 0.5 at 15 min. Co-injection of cold KF21213 and three other A 2A antagonists (KF17837, KF18446 and SCH58261), but not the A 1 R antagonist KF15372, effectively blocked uptake of [
11 C]KF21213 especially in the striatum. However, no significant effect was seen in the cortex and cerebellum. Ex vivo ARG showed a high uptake in the caudate-putamen, GP and olfactory tubercle and good uptake ratios of striatum-tocortex (4.0 ± 0.4) and striatum-to-cerebellum (3.7 ± 0.4) at 15 min post tracer injection. A PET study in rats indicated high striatal retention of [ 11 C]KF21213 at 5 min followed by a gradual decrease whereas [
11 C]TMSX uptake cleared more rapidly [66] . However, its low BBB penetration, signal-tonoise ratio and poor water solubility made it not a very practical tracer for PET studies of the CNS.
In search for more pronounced A 2A R-selectivity, 11 Clabeled iodinated and brominated xanthine analogs were synthesized and evaluated for their capability of detecting A 2A R changes in brain. In vitro binding assays showed that both IS-DMPX and BS-DMPX compounds had a high affinity and selectivity for A 2A R (Table 3) . However, because of their low in vivo uptake ratios of striatum to other brain regions and high nonspecific binding they were judged unsuitable for mapping cerebral A 2A Rs [79] .
In another PET study, the xanthine-type radioligand [ 11 C]KW6002 was reported. High striatal uptake [Standard Uptake Value (SUV) = 3.3] and low uptake in frontal cortex (SUV = 1.7) reflects specific binding [46, 64] . In a blocking study, specificity and selectivity of tracer was confirmed. However, extrastriatal regions like cerebellum and superior colliculi uptake can be seen where a low A 2A R density was reported [46, 64] [17, 73] . However, the in vivo results were remarkably different from those obtained in vitro. In an in vivo blocking study, striatal uptake was reduced by all four xanthine-type A 2A antagonists (KF17837 > KF19631 > TMSX > CSC), consistent with the in vitro result whereas non-selective AR antagonists (DMPX and XAC) and an A 1 R antagonist (KF15372) did not block tracer uptake in any region of the brain. However, SCH58621 significantly blocked striatal but not cerebellar or cortical uptake whereas three other non-xanthine antagonists (ZM241385, CP-66713, and ZD9255) did not reduce uptake in any brain region, suggesting that non-xanthine ligands may have other blocking effects than xanthine ligands [78] On the basis of the previous promising results, extensive preclinical studies (stability test, internal dosimetry data for human organs and toxicological data) were carried out to establish [
11 C]TMSX as a radioligand for imaging human A 2A R [80] . Theophylline challenge in mice resulted in a decrease of tracer uptake in the striatum, as theophylline is a non-subtype-selective adenosine antagonist. This suggested that [
11 C]TMSX-PET scan data should be interpreted with caution in patients who received theophylline. [ 11 C]TMSX was metabolically stable as about 80 % and >98 % of radioactivity in plasma and striatum represented intact tracer at 30 min post injection. From the mouse data of tissue radioactivity distribution, absorbed doses of [ 11 C]TMSX for human adults were estimated. The radiation absorbed doses in the brain (0.09 Gy / MBq) and heart (0.31 Gy / MBq) were very low. In rodents, neither mortality nor any other abnormality was found in an acute toxicity study, which was evaluated after single intraperitoneal administration of TMSX at a dose of 4.77 mg / kg and after intravenous injection of 3.3 -3.9 g / kg over a period of 15 days. An Ames test (with 4 strains of Salmonella typhimurium) suggested absence of mutagenic activity. All these findings encouraged the authors to use [ 11 C]TMSX for the assessment of A 2A R in the human brain [80] .
Clinical Studies
A first human study with [
11 C]TMSX was reported concerning myocardial imaging. The levels of radioactivity in the left ventricular lateral wall, left ventricular anterior wall and interior ventricular septum increased during the first 2.5 min post injection and then gradually decreased with time. Time-activity curves in 3 heart regions and graphical analysis using Logan plot suggested that [
11 C]TMSX was taken up via a receptor-mediated mechanism. During the 60 min study period, [ 11 C]TMSX was very stable in plasma (more than 90 % unchanged form). These preliminary findings suggested that [
11 C]TMSX-PET may be useful for myocardial imaging in the diagnosis of ischemia and other myocardial diseases [39] . This may be possible in combination with pharmacologic stress agent like regadenoson (an adenosine derivative) or with a flow tracer FDG.
An additional study evaluated [
11 C]TMSX for mapping A 2A R of skeletal muscle and heart in humans using PET. In humans, the heart was clearly visualized at baseline. Radioactivity in three regions of the heart was in line with the previous result [39] . Theophylline (a non-subtype-selective adenosine antagonist, at a dose of 100 mg / kg) slightly decreased the distribution volume (DV) of [ 11 C]TMSX in the heart (by 18 -22 %) and muscle (by 10 %) suggesting some specific binding of the tracer [40] .
Using PET, comparison of A 2A R densities in cardiac muscle has been made in both endurance-trained subjects and untrained men at resting state [35] . In addition, a group from Japan evaluated receptor functions in the skeletal muscle using PET based on their previous result [40] whereas a Finnish group recorded the myocardial perfusion effect at rest and during adenosine-induced hyperemia [41] . Higher density of A 2A Rs was found in cardiac muscle than in skeletal muscle. Also, higher levels of A 2A R were recorded in cardiac and skeletal muscle (DV of [ 11 C]TMSX in heart, 3.6 ± 0.3 vs 3.1 ± 0.4 ml g -1 , triceps brachii muscle 1.7 ± 0.3 vs. 1.2 ± 0.2 ml g -1 , respectively) of endurance-trained subjects than in untrained subjects [35] . As a follow-up the interrelation was studied between A 2A R density and myocardial blood flow (MBF) in both endurance-trained men and untrained men. Neither difference in A 2A R densities between groups nor affiliation of MBF with A 2A R density & adenosine-induced hyperemia was found [41] .
The effect of age on the distribution of A 2A R in the striatum of healthy human subjects has been studied using . There was no significant difference between calculated distribution volume ratio (DVR) of [ 11 C]TMSX in the striatum of young and elderly subjects suggesting distribution of A 2A R does not change with age. Also, no gender difference was found in elderly subjects (Females DVR = 1.37 ± 0.10, males DVR = 1.39 ± 0.06) [42] .
Kinetic modeling was carried out to investigate the behavior of [ 11 C]TMSX in the brain and to examine the usefulness of Logan plot [44] . In the study, estimation of binding potential (BP) using the Logan plot agreed to the threecompartmental model data with or without metabolite correction and arterial blood sampling. The estimated BP without metabolite correction was only 5 % lower than the true value acquired with or without arterial blood sampling [44] .
In the report [43] , the cerebral distribution of [ 11 C]TMSX was in agreement with the distribution of A 2A R known from post mortem studies in humans, rodents and primates [3, 20, 74, 75] . A two-tissue, three-compartment model was used to measure the distribution of A 2A R in the brain (n = 5) using metabolite corrected arterial input function. Specific binding was found to be 62 % in putamen. The BP was largest in the anterior putamen (1.25), posterior putamen (1.20), caudate nucleus (1.05) and thalamus (1.03) followed by the cerebellum, brainstem, posterior cingulate gyrus, occipital, temporal, parietal and frontal lobes [43] . [ 11 C]TMSX binding in human thalamus was relatively larger than in the thalamus of other mammals.
Furthermore, using [ 11 C]TMSX-PET, differences between A 2A R expression and the dopaminergic system in the striata of drug-naïve PD patients, PD patients with dyskinesia and alterations of these receptor systems after antiparkinsonian therapy were studied [45] . In order to elucidate the relationship between changes in A 2A R density and dopaminergic system in striatum, authors also used other dopaminergic system related tracers like 11 C]TMSX was increased in the putamen of PD patients with mild dyskinesia. The study also showed that A 2A Rs were significantly increased in human bilateral putamen of the drug-naïve patients after antiparkinsonian therapy [45] .
KW6002, a very potent, selective and orally active drug has completed clinical trials for the treatment of PD. In spite of extrastriatal in vivo binding result obtained in rats [64] , [ 11 C]KW6002 uptake was well characterized in human study by a two-tissue compartmental model with a blood volume component and reversible kinetics were observed during the scan time [46] . The caudate (3.38) showed the highest BP, followed by putamen (2.90), nucleus accumbens (2.37), cerebellum (2.26), and thalamus (2.19) . Oral dose of 20 -40 mg daily produced >90 % of receptor occupancy in healthy volunteers [46] . Additional study is required to determine the dose-receptor binding relationship of KW6002 in PD patients.
The design and development of new A 2A R antagonist PET tracers is a hot research topic since there are still major problems, especially with xanthine PET tracers, including high non-specific binding, reduced tracer uptake, low signal to noise ratio and barely visible target areas in the brain [60, [62] [63] [64] 66] . Usefulness of all xanthine type PET tracers may be limited due to its photoisomerisation problem, lower specific activity and selectivity towards A 2A R. On the basis of these considerations, non-xanthine compounds (Fig. 1) were developed and tested in many preclinical and clinical studies for the assessment of cerebral A 2A Rs. Below paragraphs are devoted to non-xanthine PET ligands.
Non-Xanthine Ligands
Non-xanthine [ 11 C]SCH442416 was synthesized by Omethylation of desmethyl compound using [
11 C]CH 3 I with radiochemical yield of 29 ± 7 % (decay corrected), radiochemical purity >96%, and specific activity of 1490 ± 978 mCi / mol (n = 18). Overall synthesis time was about 40 min [81] (Fig. 2) .
A two-pot radiosynthesis method was adopted using the fluorosynthon 2-[
18 F]-fluoroethyl-3,4-dibromobenzenesulfonate. The whole synthesis time including HPLC purification was about 130 min. The radiochemical yield was 15 % ± 4 % (n = 8) uncorrected for decay and the radiochemical purity was 98 % [48] .
In Vitro and Preclinical Studies
The development of the high affinity and selective novel non-xanthine compound SCH442416 as an in vivo probe for A 2A R using PET was reported Todde et al. [81] . In receptor binding studies, SCH442416 showed a very good selectivity for A 2A R as K i values were 0.048 nM for A 2A R, > 10,000 nM for A 2B and A 3 , and 1,111 nM for A 1 R ( Table 3) . Biodistribution studies showed not only radioactive uptake in the adrenal glands and kidneys, where A 2A Rs are highly expressed, but also in highly perfused organs like lung and liver radio uptake reached maximum at 5 min post injection in normal healthy rats. [ 11 C]SCH442416 penetrated the BBB easily and was retained in the brain where the maximum uptake was reached at 5 to 15 min after injection. Regional brain distribution showed a high striatal uptake (0.46 % ID / g) whereas tracer levels in the cerebellum (0.10 % ID / g) and cortex (0.10 % ID / g) were lower. Striatum-tocerebellum ratio was 4.6 ± 0.17 at the time of maximum uptake (at 15 min post injection). Two hydrophilic metabolites were found in plasma extracts (Retention time (t R ) = 4.5 and 2.5 min) with about 40 % of an intact tracer at 60 min. The regional distribution of radioactivity, the good signal-tonoise ratio and low amounts of radioactive metabolites in the brain all suggested that [ 11 C]SCH442416 was the first nonxanthine ligand suitable for mapping of A 2A R using PET [81] .
In a later study, [ 11 C]SCH442416 was tested as a new PET tracer for in vivo imaging of A 2A Rs in rat and monkey brain [85] . Preadministered A 2A R selective (SCH442416, SCH58261 and KW6002] or non-subtype selective antagonists (caffeine) decreased tracer accumulation in the striatum at 15 min after injection. Caffeine and KW6002 significantly decreased tracer retention (71 % and 68 %, respectively) in the striatum. Interestingly, subtype selective, potent antagonists like SCH442416 and SCH58621 did not yield a good blocking effect. These compounds may pose formulation problems due to poor water solubility. Receptor-specific uptake was confirmed by intrastriatal injection of quinolinic acid. Using PET, serial brain scans were made in a single monkey after injection of 30 MBq of [
11 C]SCH442416. Rapid uptake of the tracer was observed in 0 -4 min. Higher uptake in the striatum was noticed during the second frame [47] . Neither the A 1 R antagonist CPX (5 mg / kg) nor the A 2B R anatagonist alloxazine (3mg / kg) induced rotational behaviors in 6-hydroxydopamine (6 -OHDA)-lesioned mice after L-DOPA treatment. However, synergistically increased contralateral rotations were seen with the A 2A R antagonist SCH58261. In contrast, when used separately, neither SCH58261 (10 mg / kg) nor L-DOPA (2.5 mg / kg) induced rotational behaviors in this PD model. In addition, levels of A 2A Rs in 6-OHDA-lesioned mice have been determined with the A 2A R specific tracer [
11 C]SCH442416. No significant differences in striatal uptake were obseved between the two groups indicating that 6-OHDA-induced lesions of the dopaminergic system do not affect the in vivo binding of the A 2A R tracer [
11 C]SCH442416. This contrasts strongly with reported changes of A 2A R m-RNA expression in human PD [86] . Overall, this study suggested a synergistic beneficial role of A 2A R antagonists in the reduction of L-DOPA dosage in 6-OHDA-lesioned mouse model [47] .
A 2A R occupancy in Rhesus monkeys after administration of various doses of the A 1 R and A 2A R antagonist ASP5854 has been assessed using [ 11 C]SCH442416 and PET. The amount of receptor occupancy required to inhibit haloperidol-induced catalepsy (0.03 mg / kg, intramuscularly) was also determined [87] . Receptor occupancy was studied after a intravenous bolus injection of ASP5854 in animals (n = 3) and a dynamic PET scan was performed at 1, 4, and 8 hour It has been reported that [ 18 F]-MRS5425 (a [ 18 F]-fluoroethyl derivative of SCH442416) can map A 2A R changes in the rat model of PD (6-OHDA model). Also, precursor synthesis for radiolabelling and a two-pot radiosynthesis of [ 18 F]-MRS5425 were described [48] . In anesthetized rats, [ 18 F]-MRS5425 was intravenously injected and PET data were collected. The % ID / g values in regions of interest were measured in the striatum of normal rats and in rats unilaterally lesioned with 6-OHDA after intravenous administration of saline (baseline), the D 2 R agonist quinpirole (1.0 mg / kg) or the D 2 R antagonist raclopride (6.0 mg / kg). In vitro and ex vivo brain ARG showed A 2A R specific uptake in the striatum. In addition, in vivo biodistribution studies suggested radioactivity in the striatum reached a maximum at 30 and 60 min then dropped slowly. Radioactivity levels in the striatum were two-fold higher than in blood, suggesting suitability of [
18 F]-MRS5425 as an in vivo probe for mapping A 2A Rs. Results of the PET study were comparable to the previous one using [
11 C]SCH442416 in anesthetized non-human primates [85] . Radioactivity uptake was higher (9 -12 % in the % ID / g) in the lesioned striatum than in the contralateral intact side due to upregulation of A 2A Rs [48, 82] . Conflicting results (either upregulation or no change of A 2A Rs in animal models of PD) [47, 48] may be related to differences in the experimental setup and / or species differences (rat vs mice).
Clinical Studies
In an important study, A 2A R availability in 12 PD patients with and without levodopa-induced dyskinesias (LIDs) and in age-matched healthy controls (n = 6) using PET and [ 11 C]SCH442416 was reported [49] . PD patients with LIDs have elevated striatal A 2A R availability (BPs up to 1.67 vs. 0.96 of patients without LIDs). However, no correlation was found between severity of dyskinesia and increased striatal A 2A Rs. Also, the increase was not correlated to age, disease duration, levodopa equivalent unit, or Hoehn and Yahr staging. Higher A 2A R binding was found in the caudate and putamen of PD patients with LIDs with respect to both control group and PD patients without LIDs. Hence, this study suggested A 2A R antagonists might be useful for the management of LIDs along with reductions in levodopa dosage. However, to prove the concept, further studies are required in larger groups of patients. [ 11 C]SCH442416-PET might provide a robust and reliable method for in vivo investigations of A 2A R availability [49] .
[
11 C]SCH442416 has been employed to assess A 2A R occupancy by a therapeutic drug, vipadenant, in the human brain in order to correlate receptor occupancy and therapeutic effect [50] . The drug crossed the BBB and displaced receptor-bound [
11 C]SCH442416 in a dose-dependent fashion (2.5 -100 mg /day for 10 or 11 days). The estimated receptor occupancy of the drug in the brain varied from 74 % to 94 % at the lowest daily dose (2.5 mg) [46] . Unfortunately, negative findings in preclinical toxicology studies led to discontinuation of this drug in July 2010 by Vernalis Plc [88] . Thus, [ 11 C]SCH442416 might be an excellent tool for measurement of the A 2A R occupancy of various compounds (both xanthine and non-xanthine antagonists).
TRENDS IN MEDICINAL CHEMISTRY INCLUD-ING MOLECULAR DOCKING OF A 2A R ANTAGO-NISTS AS POTENTIAL PET TRACERS:
Recent developments in medicinal chemistry (both in synthesis and biological evaluation) resulted in the identification of large number of ligands with high affinity and specific binding to the A 2A R. Potential candidates for radiolabeling and molecular imaging have been reviewed below.
In the last 20 years, a number of selective A 2A R antagonists have been developed and some of them are being evaluated for treatment of PD in several preclinical and clinical studies. As shown above, A 2A R antagonists can be divided in two main categories. i) xanthine-type compounds and ii) polyheterocyclic compounds.
The xanthine scaffold present in the most popular compound caffeine represented an important starting point for the development of antagonists for this class of receptors [89] . Extensive structure-activity relationship studies among the xanthine derivatives have already led to the clinical candidates KW6002 and TMSX, both of which were labeled with carbon-11 [39, 40, 64] . However, there is an increasing interest among researchers in this field (particularly A 2A R) to explore other class of compounds (polyheterocyclic compounds) as potential PET antagonists because xanthine-type antagonists seriously suffer from low subtype selectivity and poor physicochemical properties such as photoisomerisation and low water solubility [68, [90] [91] [92] . Attempts have been made to improve water solubility of styrylxanthines such as introduction of polar groups on phenyl ring and prodrug approach with the aim not to compromise on affinity and selectivity (for example, the introduction of the sulfonate group on the phenyl ring of DMPX and MSX-3, a phosphate prodrug of MSX-2) (Fig. 4) [93] . All these studies appeal strongly to reconsider the xanthine family for A 2A R. Later, tricyclic xanthines and aminopyridopyrimidinedione derivatives (xanthine-adenine hybrid structures) were developed [92, [94] [95] [96] [97] . However, lack of affinity and selectivity made them unsuitable for further development (Fig. 4) .
Presence of adenine base, a partial adenosine structure, in CGS15943 was an important starting point for the investigation of non-xanthine compounds [93] . The 2-alkynylsubstituted adenine derivative and 1,2,3-triazole adenine derivative are the most potent compounds of this class exhibiting high A 2A R affinity (Ki, 0.95 nM and 4.7 nM, respectively) but moderate selectivity for A 2A versus A 1 receptors (Fig. 4) [92, 98] . Later, a bioisoster of CGS15943 showing good affinity and enhanced selectivity towards A 2A R was reported [99] . Pyrazolo-triazolo-pyrimidine nucleus was introduced as lead tricyclic molecule to determine A 2A R affinity and selectivity. Selected compounds of this class are SCH58621 and SCH442416 (Fig. 4) . These compounds proved to have very good affinity and selectivity for both rat and human A 2A Rs ( Table 3 ). The phenylethyl group of SCH58621 was substituted with an arylpiperazine ethyl group to obtain a new series of non-xanthines with high potency and selectivity for A 2A R. Poor water solubility is also a limiting factor for these non-xanthines [93] . However, further introduction of ether substituents gave derivatives with high affinity, selectivity and improved water solubility (SCH420814). Synthetic routes to various pyrazolo [4,3- [82, 83, [99] [100] [101] [102] . The methoxy group of SCH442416 was replaced with various conjugates like ester, carboxylic acid, amines, alkyne, fluoropropyl and fluorophore reporter groups. The fluoropropyl derivative of SCH442416 might be useful as a PET ligand after labeling with 18 F because of its good affinity (Table 3 ) towards A 2A R [83] . Pyrazole of the tricyclic moiety was replaced by an imidazole ring resulting in enhanced potency and selectivity (isomer of SCH420814) [103] . Researchers from J lich synthesized and tested oxazolopyrimidines, derived from the triazolotriazine derivative, ZM241385 and triazoloquinoxalone series as potential PET tracers for imaging brain A 2A Rs. In vitro ARG experiments indicated high nonspecific binding which conceals specific binding to A 2A Rs. In addition, triazoloquinoxaline derivatives lack good selectivity for A 2A R over A 1 R and have poor water solubility [104, 105] .
Many groups described several very potent and highly subtype-selective bicyclic and tricyclic non-xanthine analogs [84, [106] [107] [108] . Unfortunately, all the structures are not amenable to radiolabelling with 11 C or 18 F. However, more suitable candidates are: 2-[2-furanyl)-7-phenyl[1,2,4]triazolopyrimidineamine derivatives [109, 110] , triazolopurinamine analogs [98] , piperazine diamino and triamino derivatives of triazolotriazine, arylpiperazine derivatives of pyrazolotriazolopyrimidines [102] and triazolopyrimidine [92, 107, [110] [111] [112] [113] [114] which can be labeled both with 11 C (potential radiolabelling position on -NCH 3 or -OCH 3 groups) or 18 F (fluorine atom on aromatic ring). In addition to the above compounds, aminopyrimidine derivatives, benzothiazole, thiazolopyridine and 1,2,4-triazole derivatives have emerged as potential new lead molecules for the development of A 2A R antagonists [92] (Table 4) . To identify potent potential PET ligands, computer-aided drug design is of great value. Scientists made use of molecular docking software to predict the binding orientation of small molecules to their protein targets. Hence in silico docking is useful in rational drug design. Several A 2A R antagonists were docked using different software packages and protein data bank (PDB) crystal structures by different groups. A co-crystal structure of the A 2A R with the selective antagonist ZM241385 (PDB Identification number: 3EML) has been reported [115] . Important characteristic receptorligand interactions include H-bond interactions with Asn253 and Glu269 and hydrophobic interaction with Phe168.
Another study reported docking analysis of structurally diverse A 2A R antagonists with the aim to characterize the binding sites of A 2A R. They identified five transmembrane helices (TM2, TM3, TM5, TM6, and TM7], which surround the active binding site of all A 2A R antagonists [116] . These results were consistent with site-directed mutagenesis studies [117] . The three most potent xanthine analogs (KW6002, KF17837 and BS-DMPX) were first subjected to a docking study to validate the residues involved in stable binding [92] interactions between antagonists and the receptor. All three xanthine type antagonists have similar binding mode patterns. Binding energy scores of all non-xanthine analogs were in agreement with receptor affinity (K i ) of the molecules. Moreover, all compounds shared similar -interactions between receptor aromatic residues and antagonists [116] . Critical interaction for xanthine analogs was hydrogen-bonding formation between Ser277 of A 2A R with the carbonyl group of ligands whereas for non-xanthine compounds the free NH 2 groups and the oxygen in the furan ring are important features for binding to the receptor [116] .
Bidhan et al. studied in detail pyrazolotriazolopyrimidine (SCH442416) derivatives by induced fit docking methodology using GLIDE software and they reported the 2-fluoroethyl derivative of SCH442416 as a highly selective PET tracer for A 2A R [82] . This fluorinated analogue showed a similar binding mode as ZM241385 in the crystal structure whereas key interactions with important amino acids in the active site cavity such as Asn253, Phe168 and Glu169 were maintained [82] . In the study, the in silico results were fully substantiated with in vivo results.
SUMMARY AND FUTURE PERSPECTIVES
All the xanthine analogs including [ 11 C]TMSX proved to be not very suitable for molecular imaging mainly because of low signal to noise ratio, roughly visible receptor density and high degree of non-specific binding. All xanthine A 2A antagonists e.g., [ 11 C]KF17837 [46, 64, 66, 72, 78] . Through saturation binding experiment, previous studies showed that multiple binding sites and undefined binding sites of xanthine compounds are quite different from those of non-xanthine analogue's binding sites [54, 59, 65, 70, 75] . Photoisomerisation problem and specific selectivity towards A 2A R limits xanthine analogue use.
To overcome all the problems associated with xanthine type compounds, polyheterocyclic compounds were proposed, developed and tested. The regional distribution of radioactivity, the good signal-to-noise ratio and low amounts of radioactive metabolites in the brain all suggested that [ 11 C]SCH442416 was the first non-xanthine ligand being suitable for mapping of A 2A R using PET [81, 85] . However, researchers aim to develop tracers with larger striatum/cerebellum ratios than [ 11 C]SCH442416 and higher absolute values of brain uptake both in experimental animals and humans, which are important for good count statistics. In this regard, [ 18 F]fluoroethyl SCH442416 derivative was evaluated in 6-OHDA PD rat model [48] . min) allowing tracer distribution to remote imaging centers without cyclotron facilities and can achieve longer biodistribution and scanning times [82, 83] . Aminopyrimidine derivatives, benzothiazole, thiazolopyridine and 1,2,4-triazole derivatives have emerged as potential new lead molecules for the development of A 2A R antagonists and PET tracers for both therapeutic and diagnostic applications [92] . Further studies with these compounds and other fluorinated analogues of SCH442416 are warranted. Computer-aided drug design and rapid developments in medicinal chemistry may yield better radioligands for A 2A R visualization and quantification in the nearest future.
